A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC)
Completed · Phase 1/Phase 2
Conditions studied: Carcinoma, Non-Small-Cell Lung
In brief
The study consisted of a Phase 1 dose escalation/dose de-escalation portion to determine a safe and tolerable combination dose(s) of cabozantinib and erlotinib, and a Phase 2 Simon optimal 2-stage design portion with randomized assignment of subjects in an equal ratio to determine the objective response rate (ORR) of cabozantinib with or without erlotinib in subjects with non-small cell lung cancer (NSCLC) who have progressed after responding to treatment with erlotinib. The doses of cabozantinib used in this study were based on the salt weight, not the freebase weight.
Key facts
- Study ID
- NCT00596648
- Run by
- Exelixis
- People needed
- 92
- Starts
- 2008-02-12
- Expected to finish
- 2012-08-02
- Last updated by the study team
- 2026-01-13
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Katmai Oncology Group — Anchorage, Alaska, United States
- Stanford University Medical Center — Palo Alto, California, United States
- University of California, Davis — Sacramento, California, United States
- Yale University School of Medicine — New Haven, Connecticut, United States
- Georgetown University/Lombardi Comprehensive Cancer Center — Washington D.C., District of Columbia, United States
- University of Chicago Medical Center — Chicago, Illinois, United States
- Dana Farber Cancer Institute — Boston, Massachusetts, United States
- Park Nicollet Institute — Saint Louis Park, Minnesota, United States
- Summit Medical Group — Berkeley Heights, New Jersey, United States
- Case Western Reserve University — Cleveland, Ohio, United States
- MD Anderson Cancer Center — Houston, Texas, United States
- Swedish Cancer Institute — Seattle, Washington, United States
- University of Washington/ Seattle Cancer Care Alliance — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.